Europe’s deeptech boom hinges on customers, not capital—Sifted

Europe’s deeptech startups are being told to stop chasing venture capital and start chasing purchase orders. A Sifted analysis argues that the sector’s growth—fueled by a surge in quantum, biotech, and advanced materials startups—will depend less on patient capital and more on early customer adoption, particularly from risk-averse corporates and public-sector buyers.

The shift mirrors a broader tension in European tech. Just last week, investors told Yahoo Finance that the continent’s most funded startups are hitting a customer drought, not a capital crunch. Quantum startups, for example, have defied the early-stage funding gap by raising aggressively, but their long development cycles make revenue a distant prospect. Sifted’s report highlights that deeptech founders, especially women, need more than grants or VC checks—they need contracts that validate their technology and attract follow-on investment.

The call for customer obsession echoes a recent report on India’s deeptech scene, where a ₹200 crore procurement fund was framed as a more powerful funding signal than traditional capital. In Europe, the message is similar: deeptech’s next phase will be won by startups that can turn lab breakthroughs into real-world demand, not just lab funding.

What happens next will test whether Europe’s corporates and governments can move as quickly as its venture capitalists. If they don’t, the deeptech boom may leave its most promising startups stranded between prototype and scale.

Sources: sifted.eu